Cullinan Therapeutics, Inc.
CGEMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cullinan Therapeutics, Inc. focuses on Biotechnology services and products. Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company carries a $924.8M market cap, placing it firmly in the small-cap category. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Market Cap
$924.8M
Beta
-0.04
P/E (TTM)
—
P/E (Fwd)
-5.71
EPS (TTM)
$-2.99
EPS (Fwd)
$-2.52
ROE
-50.3%
ROA
-31.4%
Cash
$334.5M
Total Debt
$2.1M
Free CF
-$89.2M
52W Change
85.2%
Annual Financials
Cash vs Debt
Where CGEM stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, CGEM finished 9.83% below its 150-day moving average ($16.58) and 3.67% below its 200-day moving average ($15.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGEM overbought or oversold?
At the October 13, 2026 close, CGEM's RSI(14) was 20.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $334.5M in cash and $2.1M in debt, CGEM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$89.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Cullinan Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, CGEM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CGEM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.